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A Genetic and Molecular Analysis of Antimicrobial Agent 
Resistance in Staphylococci 
The intention of this paper is to characterize staphylococcal resistance to 
antimicrobial agents on a genetic, molecular, and biochemical level using 
seminal studies from both microbiology and molecular epidemiology as primary 
references. This review is meant to be thorough, but by no means conclusive, 
comprehensive, or fully complete. 
Discussed initially is "classical" resistance, mediated by the enzyme p-
lactamase. This includes enzyme structure, classification, identification, 
mechanisms/kinetics of action, as well as the enzyme variants, extracellularity, 
and genetics of synthesis. 
Secondly, resistance NOT mediate by p-Iactams is covered, commonly 
known as methicillin resistance. Included are the origin and dissemination of the 
mec-resistance determinant, mec-associated DNA, and the core sequence of 
mec determinant, as well as the mec regulon, PBP' function, heterogeneity in 
expression of resistance and external factors affecting resistance. Also 
discussed in detail are chromosomal genes affecting resistance level including 
the femAB operon as well as feme, femD, femE, femF, and 11m genes. In 
addition, a short summary of non mecA-mediated intrinsic resistance to p-
lactams, BORSA and MODSA, is included. 
Lastly, resistance to antimicrobial agents other than p-Iactams is 
discussed. This is primarily limited to antibiotics, although resistance to organic 
cations and inorganic ions as well as antiseptics and detergents has also been 
reported. Focused on are the most commonly known and used antibiotics, 
including aminoglycosides, chloramphenicol, macrolides, lincosamides, 
streptogramins, tetracyclines, trimethoprim and sulfonamides, fluoroquinolones, 
mupirocin, and vancomycin and teicoplanin. 
I. RESISTANCE MEDIATED BY ~-LACTAMASE 
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The first ~-Iactam antibiotic, penicillin, was discovered by Sir Alexander 
Fleming in 1929. It was first used therapeutically in 1941, and the penicillins, 
also known as the ~-Iactams, have since been used extensively and successfully 
as antibiotics in the treatment of a wide variety of bacterial infections. However, 
the first report that extracts from bacteria could destroy penicillin was published 
in 1940.1 Strains of S. aureus soon emerged that were resistant to penicillin 
because they were able to produce the enzyme ~-Iactamase, called penicillinase 
until 1960, which converts the penicillin into an innocuous form by hydrolysis of 
the ~-Iactam ring. Today, this form of antimicrobial agent resistance is 
commonplace, particularly in strains isolated from hospital environments: there 
are reports that as many as 93 percent of isolates of S. aureus are resistant to ~­
lactamase-liable penicillins.2 
To overcome the failure of ~-Iactam therapy, an intensive search has been 
underway for ~-Iactams that are not destroyed by this enzyme. This investigation 
was aided by the fact discovery that benzylpenicillin could be enzymatically 
deacylated to produce 6-aminopenicillinanic acid (6-APA). 6-APA was then 
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treated with various acyl halides to produce a variety of semisynthetic penicillins. 
Thus, it was possible to add bulky side chains to 6-APA to give, for example, 
methicillin, which is only slowly hydrolyzed by the staphylococcal ~-Iactamases, 
and cloxacillin, which is stable to acid and so can be given by mouth. Other~­
lactams produced include the carbapenems, such as imipenem. Cephalosporins 
were also developed and some of these compounds such as cefazolin and 
cephalothin are effective against ~-Iactamase-producing S. aureus. An 
extensive search was also mounted for inhibitors of the enzyme that could act in 
synergy with a ~-Iactam antibiotic that would otherwise be destroyed.3 
There has also been much research into the mechanisms by which the 
gram-positive staphylococci have evolved resistance to these antimicrobial 
agents. It is known that gram-negative bacteria produce, between them, a wide 
variety of ~-Iactamases. Evidence indicates that the introduction of modified ~­
lactams into therapy has resulted in the selection of gram-negative bacteria that 
produce mutant forms of ~-Iactamase able to hydrolyze the modified ~-Iactams. 
There is no compelling evidence, however, that S. aureus has followed this route, 
rather they have acquired a modified penicillin-binding protein that renders them 
intrinsically resistant to ~-Iactams such as methicillin, strains that are called 
MRSA. These will be discussed in detail following this first section, resistance 
mediated by ~-Iactamase, which includes accounts of the structure, mechanisms 
of action, and genetics of the staphylococcal enzyme. 
There are two main systems for classifying the ~-Iactamases. One is 
based on amino acid sequence similarity and places the staphylococcal enzyme 
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in Group A, along with many other ~-Iactamases from both gram-positive and 
gram-negative bacteria.4 The second system is based on the catalytic properties 
of the enzyme and placed staphylococcal ~-Iactamases in group 2a on criteria 
that include the ability to more rapidly hydrolyze penicillins than cephalsporins. 
Dendrograms have been constructed on the basis of sequence comparisons, 
and group 2a enzymes also appear as closely related in this system; 
consequently, the two distinct classification systems are seen to produce similar 
groupings.5 
There are four main ways to estimate the activity of the ~-Iactamases. 
The first is useful, as it can be used with crude preparations and with whole 
colonies of bacteria. Iodine is used because it reacts with penicilloic acid, the 
compound resulting from the cleavage of the penicillin ~-Iactam ring, but not with 
the penicillin. Secondly, a pH change that results from the action of the enzyme 
can be observed, which is a good assay for purified enzyme and therefore for 
detailed kinetic studies. The third method uses nitrocefin as a substrate, and 
observes a color change. This method, however, is not a very good substrate for 
the staphylococcal ~-Iactamase. Finally, differences in the absorbance between 
the ~-Iactam and its hydrolysis products can be measured. These and other 
methods have been reviewed, but it is rare for laboratories in hospital or health 
care settings to need to carry out direct testing on staphylococci for ~-Iactamase 
production.6 
Studies of the structure of ~-Iactamases effectively began with the 
determination of the arnino acid sequence of the extracellular ~-Iactamase 
5 
purified from S. aureus PC1. This form of the enzyme consists of 257 amino 
acids with a molecular weight of 28.8 kDa. The sequence has been compared 
with that of several other staphylococcal ~-Iactamases and shown to possess 
four motifs that are characteristic of many enzymes interacting with ~-Iactams. 
The PC1 enzyme has been crystallized and the structure determined to 2.0 A. All 
four common motifs are found at the presumed active site and their relative 
positions have been deterrnined by x-ray diffraction studies. There is an active 
serine protease at position 70, and it is this serine that is thought to act as the 
acceptor residue during the reaction. From these crystal structures and other 
evidence, it is predicted that ~-Iactamases behave like other serine proteases, 
such as trypsin and chymotrypsin. In serine proteases, the oxygen of the 
substrate peptide bond is in contact with the main chain-NH-groups of the two 
amino acids, which, as part of the mechanism, help create an oxyanion hole. 
The active site-serine is in contact with a histidine that acts as a general base to 
group the serine's acylation by the -C=O group of the peptide bond. Therefore, 
the peptide bond is split and an acylated enzyme is formed as an intermediate. 
The histidine then acts as a general base to activate the water molecule that 
hydrolyzes the serine ester to regenerate the deacylated enzyme. The two 
peptide bonds are consequently released.7 
The kinetics of action of ~-Iactamases have also been studied in depth. 
When discussing this, two of the most pertinent parameters of an enzyme are kcat 
and kcat I Km of kcat is a measure of the maximum number of times that an 
enzyme molecule catalyzes the reaction in a unit of time, and the Michaelis 
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constant (Km) is the substrate concentration at which one-half of the enzyme 
molecules have substrate bound at any given time. Thus, the value of kcat / Km is 
the best measure to use in comparisons of the enzyme's ability to attack 
particular penicillins or cephalosporins - the higher the value, the more rapidly 
the enzyme is likely to destroy the substrate. These parameters have been 
determined for ~-Iactamases for many substrates, and are regularly used to type 
the variants of the enzyme, as will be discussed later. 
Variants of staphylococcal ~-Iactamases have been classified into types A, 
B, C, and D on the basis of their interaction with an antiserum prepared against 
purified PC1 enzyme. Types A and C are generally produced in large amounts 
by S. aureus of phage-typing groups I and III, while type B is associated with 
phage group II isolates. Type D was discovered to be produced by strains also 
resistant to fusidic acid. The original antiserum made stimulated the activity of 
type A enzymes, but is was used up, and scientists have not been able to 
produce fresh antiserum that replicates the action of the original. However, the 
classification has been re-determined on the basis of the differing kinetic 
properties of the enzyme types. A compilation of kinetic data for the four variants 
taken from Rowland et al can be seen in figure 1. Type A can best be 
distinguished from types Band C by the large differences in the Km when 
cefazolin is the substrate. The type A enzyme has a much higher kcat for 
benzylpenicillin than that of type D. Rowland et al also found it is possible to 
make these distinctions even with whole cell preparations. There are differences 
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in types Band C, but they are not distinguishable by these parameters, it usually 
takes testing susceptibility to inhibition by tazobactum.8 
The genes for several type A, one type C, and one type 0 ~-Iactamase 
have been sequenced. There are sequence differences between the type A's, 
but the only major change that could account for the serological and kinetic 
differences between types A and 0 is the substitution of an alanine at position 
128 in the type 0 enzyme for the aspartic acid found at this position in type A. 
The sequencing of the gene for the type B enzyme is currently underway.9 Most 
MRSA strains produce a b-Iactanlase. A survey of 27 epidemiologically distinct 
MRSA strains of S. aureus conducted during the 1960's found that all 27 
produced type A ~-lactamase.1o Over 25 years later, a survey of 50 MRSA 
strains from cities in the United States revealed that 40 produced type A while 
the remaining 10 produced type C. No MRSA strain of S. aureus has been 
shown to produce either type B or type D. 11 
There is also work underway to discover whether mutations in the gene for 
~-Iactamase that specify an enzyme that more efficiently hydrolyzes some of the 
newer ~-Iactams are selected for in the natural environment. There has been 
such selection found in the gram-negative ~-Iactamases, but none has been 
documented for the staphylococcal enzyme. Whether such selection is likely for 
the whole culture is debatable because, if the enzyme is entirely extracellular, 
and an individual bacterium would probably not be at significant selective 
advantage. In contrast, staphylococci with some cell-bound ~-Iactamase could 
be at an advantage. 
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There is no good evidence as of yet that ~-Iactams can pass across the 
staphylococcal membrane. They act at the membrane surface to inhibit the 
synthesis of mucopeptide, so there is no value to the organism in having a 
cytoplasmic ~-Iactamase. The enzyme is located either at the membrane or 
released into the medium. Inspection of the predicted amino acid sequence at 
the N-terminus of staphylococcal ~-Iactamase revealed that for the type A 
enzyme there is a leader peptide of 24 amino acids. East et al discovered that 
the isolate S. aureus 1071 releases very little, if any of its enzyme into an 
extracellular medium. They found a proline at position 22 of the leader peptide in 
place of the serine commonly found at this position for other ~-Iactamases. 
Changes they directed by site-directed mutagenesis of the serine at position 22 
of the ~-Iactamase of another isolate, 3084, that produces a large amount of 
extracellular enzyme to a proline prevented the appearance of the extracellular 
enzyme. 12 The leader sequence also has a motif, including a cysteine, that is 
characteristic of a lipoprotein with a covalent bond to a glyceride, which is of 
interest because the nucleotide sequence of a signal peptidase II, which cleaves 
such lipoproteins, has been determined for a gene from S. aureus. If there is a 
lipoprotein from of ~-Iactamase in the cell membrane then it may have kinetics 
that differ from those of the free form of the enzyme. 13 The advantage of such a 
form to the bacterium could be that is has the potential to inactivate the antibiotic 
before it reaches the sensitive site at the membrane. 
For most ~-Iactamase-producing staphylococcal, the enzyme is produced 
inducibly, but the type D enzyme is produced constitutively in one strain, but 
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inducibly in others. In early studies of the induction system, several regulatory 
genes were identified, including the bfaf, the gene for a common repressor 
protein; bfaR1, thought at that time to specify a second polypeptide that bound to 
the 81al protein; and bfaR2, thought to produce a protein that could, for example, 
result in the synthesis of an intracellular inducer such as a mucopeptide 
precursor. The structural gene blaZ, together with blal and blaRI, is often found 
on the large plasmids whereas blaR2 is always chromosomal. The site for the 
blaZ gene on the chromosome is between purB and ilvB and near agr. However, 
since there is evidence for transposons containing bfaZ that may not have 
specific sites for insertion and since complete plasmids are capable of integrating 
into the chromosome, it is expected that the gene will be found in many different 
chromosomal locations. The blaZ gene was shown to be present on the 
chromosome of S. aureus PS80, but could not be transferred to a plasmid. This 
was the first indication that the gene was present on a transposon; since that 
time, several blaZ-containing transposons have been reported, including Tn552, 
Tn4002, Tn3852, and Tn4201. These are very similar to each other and 
probably have a common origin. The transposons have been shown to be 
active, in that both Tn4201 and Tn3852 have been shown to translocate - the 
former to a site near to, if not identical with, the site for blaZ mentioned above.14 
The complete sequence of Tn 552 has been determined, allowing 
significant advances in the understanding of both the transposon and of the 
regulation of ~-Iactamase synthesis. There are six open reading frames, and 
functions can be attributed to all of them. The first ORF, orf480 or transposase, 
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contains the D,D(35)E motif found in several transposases as well as in the 
integrases of retroviruses. The protein has been purified and shown to bind the 
termini of Tn552. The second ORF, orf251 , is probably an accessory 
transposition protein, important in the selection of target DNA, thought to act in a 
way analogous to the MuB protein of bacteriophage /-!. The third ORF, BinL, is a 
recombinase thought to function by catalyzing recombination at the resL site 
within Tn552. The fouth ORF, BlaZ, is the ~-Iactamase, while, as mentioned 
earlier, the fifth is the Blal, the classic repressor protein. The protein binds 
specifically to the blaZ operator region as shown by DNA footprinting and the 
protein protects two regions corresponding to the repeats found in the operator 
sequence. The protein shows 39 percent amino acid sequence identity to the 
Blal protein of B. lichenformis, which has been shown to bind to the control 
region for expression of ~-Iactamases in that organism. The sixth and final orf 
is BlaR1, a putative signal transducer-sensor protein. It consists of 585 amino 
acids and has homology with the BlaR1 's of B. lichenformis and methicillin-
resistant S. epidermidis. There are five hydrophobic regions that could span the 
bacterial membrane, so that it is possible that the N-terminus is on the inside of 
the membrane and the C-terminus is on the outside. The C-terminal region has 
motifs found for ~-Iactam binding proteins.15 
The inducer for ~-Iactam also binds to the C-terminal region of BlaR1, 
causing a signal to be passed, either directly or indirectly to the Blal protein. The 
nature of this signal is not known and it is not known whether the Blal is 
covalently modified or is modified by a noncovalent interaction with a protein or 
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small molecular weight effector. As a result of the signal the Blal no longer binds 
to the operator region and so transcription of both blaZ and blaR11blal increases, 
giving elevated synthesis of the ~-Iactamase and the regulatory proteins. 16 
II. RESISTANCE NOT MEDIATED BY ~-LACTAMASE 
(METHICILLIN REISTANCE) 
The primary target of ~-Iactam antibiotics are the penicillin-binding 
proteins (PBP's), enzymes anchored in the cytoplasmic membrane involved in 
the last stages of peptidoglycan biosynthesis. They are responsible for the 
polymerization of peptide moieties of the peptidoglycan chains, which in S. 
aureus are cross-linked by a characteristic pentaglycyl side chain. Penicillin 
reduces the cross-linking of the peptidoglycan and inhibits new septum initiation. 
The effect of ~-Iactams in staphylococci is dose dependent, extending with 
increasing concentrations from growth inhibition, to lytic and nonlytic death. The 
lethal target of ~-Iactams has not yet been identified, and penicillin-induced death 
does not necessarily coordinate with bacteriolysis. 17 
Staphylococci have different means to become resistant to ~-Iactam 
antibiotics. They can do so either by mutation, or more efficiently and more 
clinically relevant, by acquisition of a foreign DNA element coding for methicillin 
resistance. The methicillin resistance determinant mec confers to the 
staphylococci an intrinsic resistance against all ~-Iactams, including 
carbapenems and cephalosporins. As stated in the introduction, the first 
methicillin resistant S. aureus (MRSA) containing the mec determinant were 
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isolated in 1960, shortly after the introduction of methicillin into clinical use. At 
that time, MRSA compromised less than 1 percent of all isolates, but they have 
since spread successfully all over the world. 18 MRSA reside mainly in 
environments in which there is a constant strong antibiotic pressure, such as 
hospitals. Once established, MRSA is difficult to control and eradicate. 
A further property of MRSA is their tendency to accumulate unrelated 
resistance determinants and incorporate them into their genome. Their 
adaptability and ready response to antibiotic selection has led, in about 40 years, 
to the evolution of MRSA strains resistant to almost all commonly used 
antibiotics. MRSA have become a serious problem because of both their 
multiresitance, and their intrinsic resistance to ~-Iactam antibiotics, ruling out 
therapy with many currently used antibiotics. Another clinically less important 
class of staphylococci has appeared with borderline resistance to methicillin. 
Although these isolates can sometimes be mistaken in susceptibility tests for 
MRSA, they carry no mec determinant, are usually not multiresistant, and arise 
by mutation at additional non-mec loci and as a result of selection for 
resistance. 19 
The mec determinant resides on a DNA element of more than 30 kb that is 
absent in susceptible staphylococci. In all strains examined by scientists so far, 
this DNA element seems to integrate at a specific site in the S. aureus genome, 
between the spa (protein A) and purA (adenine requirement) genes found to be 
located on the Sma-I-G fragment of S. aureus. Neither the nature or origin of this 
element nor the mechanisms by which it is transferred are currently known. The 
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transient capture of the mec determinant on a plasITlid by Trees and Landolo 
suggest that it resides on a transposon Tn4291.2o It is believed that the early 
MRSA isolates descended from one single methicillin resistance clone, however 
since then, the mec determinant seems to have entered other phylogenetic 
lineages of S. aureus. 
It is also possible that the mec determinant was acquired at different times 
by different strains and that additional mutations and deletions have served to 
further diversify the mec-associated DNA as well as the genome of the host. 
Clonal analysis of MRSA strains and of the mec determinant stemming from 
staphylococcal species other than S. aureus, mainly S. epidermidis and S. 
haemolyticus, supports the hypothesis that there may be a dissemination of the 
mec determinant by horizontal transfer, with the CoNS serving as the reservoir of 
the mec determinant for S. aureus. ~-Iactamases, which are transposon and 
plasmid encoded were rapidly and widely disseminated and are now widely 
present in about 80 percent of all staphylococci. In contrast, the mec 
determinant is still restricted to a few clonal lineages and seems to favor clonal 
over horizontal spread.21 
The core sequences of the mec element consist of mecA, a gene coding 
for a low-affinity penicillin-binding protein, termed PBP2' or PBP2a, which is 
prerequisite of methicillin resistance, and a variable segment of 3' DNA that ends 
in an insertion sequence-like element, named IS43111S257. The variable part 
codes for an open reading frame that has amino acid similarity with E. coli 
phosphodiesterase (UgpQ) and for a direct repeat unit (dru) containing 10 
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degenerate 40-bp repeats of unknown function. The length of the fragment 
between mecA and IS431 mec is hypervariable, owing to a deletion within the dru 
element and postinsertional rearrangements between the IS element and the 
hypervariable region. This variability is utilized for epidemiological studies, using 
CIa I restriction site polymorphism of the mec determinant, or size variations after 
amplification of the dru element for molecular typing of MRSA.22 
Another clinically important feature, and the likely reason for the frequent 
association of multiresistance with methicillin resistance, is the fact that mec-
associated DNA acts as a trap for the integration of other unrelated resistance 
determinants in that chromosomal segment. IS431mec thereby serves as target 
for homologous recombination of other resistance determinants or plasmids 
flanked by similar IS elements. Transposon attachment sites found 5' to mecA 
are also responsible for the site-specification of transposon Tn554. Whereas the 
mec determinant of earlier clinical isolates was stable, in more recent isolates, 
which have accuITlulated more resistance determinants, and therefore contain 
several direct repeats of IS43111S257, spontaneous deletions removing the mec 
determinant or part of it have been observed, sometimes even deleting nearby 
chromosomal genes.23 
From the more than 30 kb of additional DNA contained in the element 
which is absent from susceptible strains, only a small part, namely the sequence 
carrying the mecA gene, is sufficient for producing methicillin resistance in 
susceptible strains. Its product is a low-affinity 76 kDa PBP2' that shows the 
characteristics of a membrane-bound PBP, with a putative transglycosylase 
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domain and the characteristic conserved sequences of a transpeptide. Its 
transglysosylase domain is sometimes degenerated, as most ITlutational events 
among different mecA genes that had no effect on the methicillin resistant 
phenotype were found in the putative transglycosylase domain. The highly 
conserved sequence similarity between the mecA genes of several unrelated 
methicillin-resistant S. aureus and S. epidermidis strains, suggest little time has 
passed since the mecA gene entered the staphylococci. 24 
As stated before, the mecA origin is unknown, but it is likely that the 
sequence stems from an organism with a high AT content, similar to 
staphylococci. It has been proposed that the mecA sequence arose by 
recombination between the promoter and N-terminal sequence of a penicillinase 
gene and the structural gene of a PBP of unknown origin. Upstream of mecA, 
some mec determinants contain a divergently transcribed regulatory element, 
holding the genes mecR1 and mecl, separated from mecA by its promoter and 
operator. mecl, the repressor of mecA, has strong similarity to Blal, the repressor 
of staphylococcal p-Iactamase. mecR1 is similar to, and has the same molecular 
organization, as BlaR1, which is involved in the induction of staphylococcal P-
lactamase. It contains several hydrophobic transmembrane segments, an 
extracellular penicilloyl serine transferase motif, and a cytoplasmic Zn-peptidase 
motif.25 
In the absence of mecl-mecR1 and p-Iactamase regulatory elements, 
there is a constitutive PBP2' production. Some strains that harbor a complete 
functional mecl-mecR1 regulatory element are strongly repressed and produce 
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PBP2' only after induction. Induction is slow in these strains, and methicillin and 
oxacillin seem to be weak inducers. Consequently, methicillin resistance is 
established very slowly with full induction on methicillin-containing plates seen 
only after about 48 hours. Such strains may appear falsely susceptible in 
standard resistance tests. However, clinical strains that carry the sequences for 
mecl and mecR1 produce PBP2' constitutively and in high amounts. They are 
usually found to have point mutations or deletions that inactivate the repressor.26 
Because of their great similarity to MecR1 and Mecl, the regulatory 
elements BlaR1 and Blal of the staphylococcal ~-Iactamases can also regulate 
mecA transcription. Repression by Blal is weaker than by Mecl, but there is still 
some PBP2' produced in the uninduced strain, and induction by methicillin is as 
rapid as ~-Iactamase induction. Since staphylococcal ~-Iactamase and PBP2' 
share the same induction pathways, the putative chromosomal locus blaR2 that 
is proposed to interfere with the bla regulon may also affect mecA regulation. 
The mechanisms of the induction cascade and its components, which lead from 
the extracellular ~-Iactam to the different factors involved in signal transduction to 
the final induction of either ~-Iactamase or PBP2', remain to be found in 
staphylococci.27 
It is generally believed that PBP2', which has the binding characteristics of 
a normal PBP, acts as a transpeptidase, and that it takes over the functions of 
the resident PBP's of the cell when activated by high concentrations of ~­
lactams. Under normal growth conditions, in the absence of ~-Iactams, PBP2' 
does not seem to contribute to cell wall composition. Profound differences only 
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become apparent when the normal PBP's of the cells are inactivates by ~­
lactams and solely PBP2' is left functional. Whereas more than 60 percent of 
muropeptides in the wall of normal growing cells are cross-linked, cross-linking 
decreases to 15 percent in the presence of methicillin, suggesting that PBP2' is 
restricted to the formation of muropeptide dimers only. Nevertheless, it is still 
possible that PBP2' has an additional unknown role in resistance. Interestingly, 
the transfer of a resistant strain that constitutively produces PBP2' from a drug-
free medium to a high concentration of methicillin induces a lag period in growth 
roughly proportional to the methicillin concentration in which it was placed. This 
was postulated to be related to the activation of a regulatory circuit that switches 
cell wall synthesis from the normal PBP's to PBP2' .28 
Besides studying the PBP's of staphylococci, much research has gone 
into the heterogeneous expression characteristic of the methicillin-resistant 
strains. When an overnight culture of a MRSA strain is plated on increasing 
concentrations of methicillin or on any other ~-Iactamase resistant ~-Iactam and 
the colony-forming units are determined, only a small fraction of the total 
population is able to grow at much higher concentrations than the majority. The 
concentrations up to which most of the cells grow is commonly called the basal 
resistance level. 29 There have been observations that the population analysis 
profile is also growth phase dependent, which suggests that whatever changes 
are triggered by methicillin that allow resistance above the basal level are cell 
cycle dependent. In some strains, the highly resistant subpopulation will keep 
the high resistance once it has been formed, and descendents of this 
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subpopulation will remain resistant to those concentrations of methicillin to which 
they were selected. The stability of these subclones suggests that they may also 
be mutants. On the other hand, in some clinical isolates, the subclones return to 
their original resistance upon regrowth from a single colony in drug-free medium. 
This could be explained by assuming that the initial level of resistance was due to 
the induction of methicillin resistance and that induction was lost upon regrowth 
on drug-free medium, demonstrating the different mechanisms that may lead to 
high resistance. 30 
Clinical isolates carrying the mec-determinant vary widely in their basal 
resistance to methicillin (MIC's of less than 4 ug/ml to greater than 1,000 ug/ml), 
as well as in the ratio of cells able to develop high methicillin resistance. Since 
population profiles are a strain-specific property that can be reproduced under 
strictly controlled conditions, clinical isolates have been arbitrarily divided into 
four classes of expression by Tomaz et ai, although it is not clear that each of 
these classes corresponds to a single mec/host background.31 Despite many 
efforts such as this, there currently exists no satisfactory model that can explain 
the mechanisms governing heteroresistance. Rearrangements involving the 
mec determinant have been observed in strains after selection for high methicillin 
resistance, but they were shown not to be responsible for increased resistance.32 
Slow inducibility of mecA when controlled by a strong repressor, as in strains with 
mecR1-mec/, can lead to low resistance. It has also been shown that repression 
of mecA by the ~-Iactamase repressor turns a highly and homogeneously 
resistant MRSA into a heterogeneously resistant strain, when the corresponding 
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signal transducer, needed for induction (BlaRI) is inactivated.33 This means that 
a certain threshold of PBP2' is needed for the expression of methicillin 
resistance. However, in strains with constitutive PBP2' synthesis, which vastly 
overproduce this protein, the same amount of PBP2' is present whether the cells 
are heterogeneously or homogeneously resistant. A number of studies have 
been unable to establish a correlation between the amount of PBP2' production 
and resistance levels, suggesting that other genes cooperate with PBP2'. 34 
In contrast, a series of experiments showed that a chromosomal gene(s), 
termed chr*, was responsible for the expression of high level resistance, and that 
neither mecA nor any of the additional mec-associated DNA was involved. A 
similar conclusion, namely that the chromosomal background of the 
staphylococcal strain plays an important role in determining resistance levels, 
was drawn from another experiment. Homogeneous high-level methicillin 
resistance was abolished by insertional activation of mecA. Methicillin resistance 
could be restored to its original high resistance level by reintroducing mecA even 
though its gene came from a low-level heterogeneously resistant strain. The 
functions of genes involved in high-level methicillin resistance such as chr* 
remain to be identified, however a chromosomal segment that may mediate high-
level resistance was recently cloned. Characterization of genes such as this may 
help clarify the differential expression of resistance. 35 
External factors, such as temperature, pH, osmolarity, light, divalent 
cations, chelating agents, and anaerobiosis can also affect methicillin resistance. 
Lowering the temperature and increasing NaCI concentrations enhances 
methicillin resistance, and these conditions are routinely employed in the 
detection of methicillin resistance in clinical isolates. However, which genetic 
elements respond to these external factors in staphylococci and how they are 
connected to the methicillin resistance are still unknown.36 
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Signal transduction may also play an important role in methicillin 
resistance. Substances that are able to interact with the cell membrane, such as 
surfactant glycerol monolaurate, were shown to inhibit ~-Iactamase induction, 
probably by interfering with signal transduction. The detergent Triton-X1 00, 
which stimulated both the release of acylated lipoteichoic acids and bacterial 
autolysis, was shown to reduce methicillin resistance when added in 
subinhibitory concentrations. The effect is similar to that of polidocanol, a 
nonionic detergent, which has been shown to increase the susceptibility of MRSA 
to ~-Iactam antibiotics. 37 These substances presumably act at the cell 
membrane level, disturbing signal transduction and enhancing ~-Iactam action by 
interfering with cell wall metabolism. Mutants resistant to these effects might 
help identify additional factors involved in ~-Iactam action and resistance. 
Tn551-mediated insertional mutagenesis of the staphylococcal genome 
has been used to generate susceptible mutants from a methicillin resistant strain. 
The genes identified were termed factors essential for methicillin reistance (fern) 
or auxiliary (aux) factors. These Tn551-mediated inserts were then mapped and 
found to be numerous and scattered around the staphylococcal genome. 
According to the effect of their inactivation on methicillin resistance, they can be 
separated into two classes. I nserts in femA and femB abolish methicillin 
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resistance completely, including even the formation of a highly resistant 
subpopulation. Other factors, such as feme and femD, reduce the basal 
resistance level but still allow formation of highly resistant revertants. All of these 
factors belong to the normal set of genes of the staphylococcal genome of both 
susceptible and resistant strains and are involved directly or indirectly in specific 
steps of cell wall biosynthesis. Inactivation of these factors in a susceptible strain 
results in hypersusceptibility to ~-lactams.38 
The femAB operon was mapped downstream or trpA in the Sma I-A 
fragment in S. aureus 8325. It is involved in the peptidoglycan pentaglycine 
interpeptide bridge formation. Mutants that lack FemS are able to attach only 
three glycines to the cross-bridge. No femA zero mutant is available, but 
peptidoglycan composition of a polar mutant allowing less than 10 percent of 
femAB transcription suggests that FemA directs incorporation of glycines two and 
three. The first glycine appears to be added independently of FemA and 
FemS.39 The precise role of these two cytoplasmic proteins, which are very 
similar to one another and have an approximate size of 49kDa, is unknown. The 
glycines are added to the peptidoglycan stem-penta peptide by three glycyl-
tRNA's that are specific for cell wall synthesis and different from the glycyl-tRNA 
used in protein biosynthesis. In S. aureus, glycine is loaded on each of these 
tRNA's by a single glycyl t-RNA synthetase. However, FemA and Fen1S lack 
homology to any published protein sequences, including glycyl t-RNA 
synthetase. Therefore, it is not possible to predict their precise functions.4o 
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The long flexible pentaglycine side chain is responsible for the high cross-
linking values characteristic of the staphylococcal peptidoglycan. The shortened 
glycine side chain in femAB mutants leads to reduced peptidoglycan cross-
linking and to higher resistance to lysostaphin, a glycyl endopeptidase. 
Additional defects in femAB mutants include aberrant septum formation, 
thickened cross walls, and a retarded cell separation. Neither PBP2' synthesis 
nor that of the normal PBP's is affected in femAB mutants. PBP's are produced 
in normal amounts, but their function is impaired - the cells become 
hypersusceptible to ~-Iactams. This is clinically significant because inhibition of 
FemA of FemB to any antibacterial agent should therefore restore the efficacy of 
~-Iactams against MRSA. 
The feme and femO loci were also found to be located on the 
chromosomal Smal-A fragment of the S. aureus 8325 chromosome. Inactivation 
of feme reduces only the basal resistance level in MRSA but still allows 
formation of a highly resistant subpopulation. The feme mutation produces a 
metabolic block in glutamine production. Inactivation of the glutamine synthetase 
repressor (glnR) has a polar effect on transcription of the 3' glutamine synthetase 
gene, gInA, in the glnRA operon, leading to reduces production of glutamine 
synthetase and consequently to a lack of glutamine. This has an indirect effect 
on peptidoglycan composition, reducing the degree of cross-linking in the 
peptidoglycan. Addition of glutamine to the growth medium can restore 
methicillin resistance. The mutation femO interferes with peptidoglycan 
precursor production. It has been postulated to be a defect in a gene controlling 
the rate of biosynthesis of the unsubstituted disaccharide pentapeptide 
precursor. 41 
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Little information is available on femE, although it has been identified as a 
Tn551 insertion in the Smal-A fragment, in a site distinct from femAB and feme. 
No significant changes in peptidoglycan composition were detected in this 
mutant.42 femF mutants are impaired in an early step of precursor muropeptide 
synthesis and the gene has been localized to the Smal-B fragment. 43 
In addition to the fern (factors associated with methicillin resistance), a 
gene, 11m, coding for a 38-kDa lipophilic protein, has been identified that 
increases autolysis rates and reduces methicillin resistance upon inactivation, as 
do the fem factors. The 11m gene has been identified in all S. aureus strains, but 
has not been found in other staphylococcal species. 11m shows strong similarities 
to mra Y, the first enzyme involved in the lipid cycle of peptidoglycan 
biosynthesis.44 From the growing list and functions of fem factors, it seems that 
any disturbances in the well-balanced biosynthesis of peptidoglycan and possibly 
alterations in membrane composition as well, reduce the optimal function of 
PBP2' when resident PBP's are saturated by methicillin. As previously stated, 
the fem factors seem to belong to the normal housekeeping genes of 
staphylococci and apparently function normally in clinical methicillin-resistant 
isolates. Although their experimental disruption by transposon insertion leads to 
a reduction in methicillin resistance, it is not clear that any of the fem genes or 
loci are directly involved in the expression of methicillin resistance in clinical 
isolates or that they are altered in their expression or function by the presence of 
the mec determinant. Future studies could possible use techniques other than 
gene inactivation to find these resistance-associated factors. 
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Unlike the femAB mutants, the femC, femO, and 11m mutants produce a 
small number of highly methicillin-resistant revertants when plated on high 
concentrations of methicillin. Reversion takes place in a site distant from the 
corresponding fem or 11m mutation. In femC mutants, this reversion affects an 
unidentified gene(s), termed hrmC (for high methicillin resistance reversion in 
femC), and does not restore the glutamine synthetase activity. The 
corresponding hmrO revertants of femO and the highly resistant revertants of 11m 
likewise occur at sites involving neither femO nor 11m. These revertants are 
highly and homogeneously resistant, similar to the highly resistant subpopulation 
formed by a heterogeneous MRSA in the presence of high concentrations of 
methicillin. However, the chromosomal chr* mutation involved in high-level 
resistance of wild-type MRSA strains could not substitute for the hmrC mutation. 
This means that in MRSA, rnultiple paths may lead to high-level resistance.45 
Standard susceptibility tests sometimes fail to distinguish between an 
MRSA with a very low level basal resistance and the clinically less relevant 
borderline resistant strains mentioned earlier that carry no mec determinant. 
Two types of borderline resistant strains have been encountered: BORSA and 
MODSA. The first type, termed BORSA, are hyperproducers of ~-Iactamase or 
strains specifically producing a methicillinase. This resistance mechanism is not 
intrinsic because it involves partial hydrolysis of penicillinase-resistant penicillins. 
However, it appears that their hyperproduction of ~-Iactamase is not sufficient, 
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and that specific, yet-to-be defined host background factors are also needed to 
establish borderline resistance.46 
The second type of borderline resistant isolates, termed MODSA, are 
strains with modifications in their own PBP's. Such strains can also be obtained 
in vitro from a susceptible S. aureus and selected for growth on increasing 
concentrations of ~-Iactams. Multiple factors that have yet been identified are 
involved in this process, and changes in the amount and/or affinity of the existing 
PBP's of the cells have been described. Increase in resistance by this 
mechanism is usually impaired with decreasing growth rates. In contrast to 
mecA-dependent methicillin resistance, no heteroresistance is observed in 
MODSA strains all descendents of the culture are uniformly resistant.47 
Clinically, neither the BORSA nor the MODSA have become as relevant as 
MRSA but, because of their phenotypic overlap with low-level resistant MRSA, 
identification methods have been used that can distinguish between the 
presence or absence of the mecA gene. 
In April 2001, Kuroda et al publishes the genome sequence (about 2.8 
million base pairs) for two strains of MRSA, Mu50 and N315.48 Many believe this 
is the breakthrough needed to finally begin to "win" the struggle against MRSA. 
III. RESISTANCE TO ANTIMICROBIAL AGENTS OTHER THAN ~-LACTAMS 
Resistance to a wide range of antimicrobial agents, including antibiotics, 
antiseptics/disinfectants, and inorganic or heavy metal ions, has been reported in 
S. aureus and other staphylococci.49 In many instances, the resistance elements 
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are either plasmid-encoded or associated with other mobile genetic elements. 
These determinants mediate resistance through a number of different 
biochemical mechanisms that can be classified into several common categories: 
inactivation mechanisms, bypass mechanisms, target site alteration, efflux 
mechanisms, and sequestration. 
In the first example, the antimicrobial agent is inactivated by chemical 
modification by either intracellular or extracellular detoxifying enzymes (e.g. the 
inactivation of chloramphenicol by chlorarnphenical acetyltransferase). 
Secondly, staphylococci can bypass the effect of the antimicrobial agent by 
substitution of an alternate pathway or enzyme, as in resistance to trimethoprim 
due to the synthesis of an alternative trimethoprim-insensitive dihydrofolate 
reductase enzyme. Thirdly, target site alteration leads to a reduced affinity of the 
target site for binding with the antimicrobial agent, as is observed with in 
resistance to macrolides, lincosmaides, and streptogramin (MLS) type B 
antibiotics, where there target site is structurally modified (methylation of the 23S 
rRNA adenine residues). Fourthly, the antimicrobial agent can be actively 
pumped out of the bacterial cell (e.g. the active export of toxic organic cations). 
Lastly, the antimicrobial agent can be specifically and stoichiometrically bound by 
a cellular protein such that its antimicrobial action is blocked, an example of 
which can be seen in the binding and sequestration of bleomycin. Some of these 
examples and others will be discussed in detail in the next sections. 50 For each 
antibiotic, examples of each will be given along with their mechanism of action 
and prevalence of use for staphylococcal infections. Also discussed will be 
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cloning and sequence analysis of proposed resistance determinants, location 
(where they are located chromosomally, types of plasmids, etc), and homology to 
other known determinants, as well as other factors relevant to describing the 
genetic and molecular bases of resistance. 
AMINOGL YCOSIDES 
Aminoglycoside antibiotics, including gentamicin, kanamycin, 
streptomycin, and neomycin, inhibit protein synthesis by binding to the 30S 
ribosomal subunit. Aminoglycosides have been widely used to treat 
staphylococcal infections and are still used in combination with other 
antistaphylococcal agents. The major mechanism of aminoglycoside resistance 
observed in the staphylococci is drug inactivation by cellular enzymes, such as 
aminoglycoside acetyltransferases (AAC), adenyltransferases (AAD), or 
phosphotransferases (APH). Aminoglycosides modified at the amino groups (by 
AAC's) or hydroxyl group (by AAD's or APH's) lose their ability to bind 
ribosomes, and hence, do not inhibit protein synthesis.51 
Resistance to gentamicin and concomitant resistance to tobramycin and 
kanamycin in the staphylococci is mediated by a bifunctional enzyme displaying 
both AAC And APH activity, which has been purified and characterized 
biochemically. 52 The aacA-apdD gene encoding this enzyme has been cloned 
from the plasmid pSK1 and sequenced. Amino acid sequence analysis suggests 
that it contains two separate domains, an N-terminal domain with homology to 
AAC enzymes and a C-terminal domain with homology to APH enzymes. 
Mutagenesis of the aacA-apdD gene supports the notion that two separate 
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domains in this enzyme are responsible for the two aminoglycoside-modifying 
activities. The aacA-apdD gene has been shown to be encoded on the 
composite transposon Tn4001. Tn4001 and Tn4001-like elements have been 
found to be widely distributed in both S. aureus and CoNS, being found on pSK1 
family plasmids, conjunctive plasmids, occasionally on p-Iactamase/heavy metal 
resistance plasmids, and also in various chromosomallocations. 53 
Resistance to neomycin, kanamycin, tobramycin, and several other 
aminoglycosides in the staphylococci is mediated by an AAD encoded by the 
aadD gene. The aadD gene is often carried on small plasmids, such as pUB11 O. 
The complete nucleotide sequence of pUB11 0 has also been determined, and 
the AAD product of aadD has been purified and biochemically characterized. 
Copies of the aadD-encoding pUB11 O-like plasmids have also been found 
integrated into large conjunctive plasITlids and into the methicillin resistance mec 
region of the chromosome of some S. aureus isolates. Additionally, a variety of 
other plasmids encoding AAD have been detected and probably also carry an 
aadD gene. 54 
Staphylococcal streptomycin-resistance genes have also been identified. 
Sequencing of the streptomycin resistance gene str, identified on small plasmids 
such as pS 194, has demonstrated that its product is homologous with AAD 
enzymes fron1 other bacteria. High-level streptomycin resistance has been 
associated with chromosomal mutations (strA) that affect the ribosome. Low-
level cross-resistance to most aminoglycosides appears to be due to a 
chromoson1al mutation that affects the membrane's permeability to 
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aminoglycosides. A streptomycin resistance APH encoded by an aphC gene has 
also been found in S. aureus, but not well characterized. Additionally, a plasmid-
borne aadA gene encoding an AAD that confers resistance to streptomycin and 
spectinomycin has been detected.55 
CHLORAMPHENICOL 
Chloramphenicol is a bacteriostatic antibiotic that binds to the 50S 
ribosomal subunit and inhibits the transpeptidation step in protein synthesis. It 
has not been widely used as an antistaphylococcal agent, however resistance to 
chloramphenicol in the staphylococci has been reported and is due to the 
inactivation of the antibiotic by a chloramphenicol acetyltransferase enzyme 
(CAT), which acetylates the antibiotic.56 cat genes have been located on a wide 
variety of staphylococcal plasmids, and three main families of cat-encoding 
plasmids have been identified, typified by the plasmids pC194, pC221, and 
pC223. The nucleotide sequences of the cat genes on S. aureus plasm ids such 
as these have been determined and their products are homologous both with 
each other and with cat enzymes from other bacteria. Expression of the cat gene 
is typically inducible and has been studied in detail in the case of the pUB112 cat 
gene. Expression seems to be regulated by translational attenuation in a similar 
manner to ermC expression, which will be discussed in the next section. The 
cat gene is preceded by a 9-amino acid leader peptide, and the leader mRNA 
can form a stable stem-loop structure, which masks the ribosome binding site of 
the cat gene. Chloramphenicol appears to cause the ribosome to stall on the 
leader sequence, opening the stem-loop structure, thereby exposing the cat 
ribosomal binding site, allowing cat expression, and therefore resistance to 
chloramphenicol. 57 
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MACROLIDES, LlNCOSAMIDES, STREPTOGRAMINS (MLS) 
Macrolides, such as erythromycin and oleandomycin; lincosamides, such 
as lincomycin and clindamycin; and streptogramin antibiotics have a 
bacteriostatic effect sin1ilar to that of chloramphenicol - by binding the 50S 
ribosomal subunit and arresting protein synthesis. Erythromycin, clindamycin, 
and lincomycin have been used extensively in the treatment of both minor and 
major staphylococcal infections. Currently, resistance to these agents is highly 
prevalent among the staphylococci. Streptogramins, such as pristinamycin, 
have been used in Europe as antistaphylococcal agents, but the prevalence of 
resistant strains remains IOW.58 A number of determinants conferring resistance 
to this group of antibiotics via a variety of mechanisms have been identified in the 
sta phylococci. 
Three homologous staphylococcal determinants, ermA, ermB, and ermC 
have been identified that confer resistance to the MLS antibiotics by target-site 
alteration of the ribosome. The best example of these genes, ermC, has been 
demonstrated to encode a methylase, which catalyzes the dimethylation of an 
adenine residue in the 23S ribosomal subunit, thereby reducing the affinity 
between the ribosome and the MLS antibiotic. The ermC gene is typically carried 
on small staphylococcal plasmids, such as pE194, and its expression is inducible 
and is regulated at the level of mRNA secondary structure, as has been thought 
for cat regulation. The ermC mRNA contains a leader sequence coding for a 19-
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amino acid leader peptide, and this leader mRNA is capable of forming a stable 
stem-loop structure that sequesters the ermC binding site. Erythromycin-induced 
stalling of the ribosome during translation of the leader sequence opens up the 
stem-loop, permitting ribosomal access to the ermC ribosomal binding site and 
subsequent translation of ermC. Both genetic and physical evidence strongly 
support this model of translational attenuation and have suggested that codons 5 
to 9 of the leader sequence are essential for induction while codons 9 and 10 are 
in physical contact with the stalled ribosome. Although ermC-encoded MLS 
resistance is characteristically inducible, both naturally occurring and in vitro 
mutants of ermC have been isolated that express constitutive MLS resistance. 59 
The ermA gene also confers inducible resistance to MLS and has been 
shown to be encoded on the transposon Tn554. Tn554 also carries the 
streptomycin resistance spc gene encoding an adenyl transferase, similar to AAD 
of aminoglycoside-resistant strains. The cornplete sequence of Tn554 has been 
determined and the ermA gene demonstrated to encode a product homologous 
to the RNA methylase encoded by ermC. Tn554 has been shown to insert at a 
specific site in the S. aureus chromosome but has also been found at a number 
of chromosomal sites, including within the mec region and may also be plasmid 
located. The ermA gene is preceded by a leader sequence coding for a 19 
amino-acid peptide homologous with the ermC leader peptide. This suggests 
that ermC is also regulated by translational attenuation; supporting this, 
erythromycin-induced stalling of the ribosome on the ermA leader has been 
observed. Erythromycin may also playa role in stabilizing the ermA mRNA. 
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The ermB gene confers constitutive resistance to MLS and has been 
detected on some ~-Iactamase/heavy metal plasmids where it is encoded on the 
transposon Tn551. Transposition of Tn551 has been demonstrated in vivo and 
the transposon has been partially sequenced at this time. 60 
Distinct from the erm genes, msrA gene confers resistance only to 14-and 
15-member macrolides, such as erythromycin, and to type B streptogramins, 
possibly by an efflux mechanism. msrA is frequently plasmid encoded and is 
widely disseminated in clinical S. epidermidis strains, as well as being found in S. 
aureus strains. msrA has been cloned and sequenced from the S. epidermidis 
plasmid pUL5050 and found to encode a hydrophobic protein with sequence 
similarity to the ATP-binding components of the ABC superfamily ATP-dependent 
transport systems. The region upstream of msrA resmbles the control regions of 
ermAIC genes regulated by translational attenuation. 61 Epidemiologic studies of 
erythromycin resistance have indicated that ermC and msrA are the most 
frequent causes of erythromycin resistance and that ermA and ermB are only 
present in a minority of isolates.62 
TETRACYCLINES 
Tetracycline and related antibiotics are bacteriostatic agents that bind to 
the 30S ribosomal subunit, preventing stable association with the aminoacyl-
tRNA, resulting in the inhibition of protein synthesis. Tetracycline is a very 
commonly used antibiotic, but has not been widely used for treatment of 
staphylococcal infections, however a semi-synthetic tetracycline, minocycline, is 
used in some countries for treatment of multi-resistant staphylococcal strains.63 
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Two different resistance mechanisms to tetracycline have been identified in the 
staphylococci. First, the chromosomally encoded tetA(M) gene confers 
resistance to tetracycline and to semisynthetic analogues, including minocycline, 
by a mechanism known as ribosomal protection. The tetA(M) gene from a 
clinical S. aureus isolate has been cloned and sequenced and found to share a 
high level of sequence sirrlilarity at the nucleotide and amino acid level with class 
M tet determinants from other gram-positive and-negative organisms. Southern 
hybridization analysis has suggested that there is no indication that tetA(M) in S. 
aureus is located on a transposable element. Expression of tetA(M) gene has 
been shown to be induced by the tetracycline. The TetM protein shares 
sequence sirrlilarity with elongation factor G, which translocates the peptidyl-
tRNA during protein synthesis, and other GTP-binding proteins. tRNA 
modification activity has been suggested to be necessary for TetM-mediated 
tetracycline resistance, but to date, the biochemical basis remains unclear. One 
possibility is that TetM stabilizes the ribosome-tRNA interaction in the presence 
of tetracycline.64,65 
The second tetracycline resistance mechanism identified in staphylococci 
is active efflux that can be encoded by either of to determinant tetA(K) or tetA(L). 
Both confer inducible resistance to tetracycline, but not its semisynthetic 
analogues. tetA(K) is found on small plasmids, and also has been found 
chromosomally due to IS257-mediated integration of a plasmid. tetA(K) has 
been cloned an sequenced from staphylococcal plasmids. tetA(L) is also 
typically found on small plasm ids in Bacillus sp., but it also has been seen in 
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staphylococci. Both tetA(K) and tetA(L) are probably regulated by translational 
attenuation in a similar manner to that of cat, ermA, and ermC expression. The 
products of tetA(K) and tetA(L) are homologous to each other, as well as to a 
range of drug efflux proteins in the major facilitator superfamily, some of which 
are discussed later. TetK and TetL are both thought to be membrane proteins 
with 14 transmembrane-spanning segments. Like other members of the major 
facilitator superfamily, TetK and TetL mediate drug efflux driven by the proton 
motive force (pmf) of the transmembrane electrochemical proton gradient, rather 
than by ATP hydrolysis. Transport assays have indicated that tetK confers 
tetracycline resistance - assays of tetracycline uptake in everted membrane 
vesicles have indicated that TetK is functionally similar to the well-characterized 
TetB tetracycline efflux pump encoded in enterobacteria. In a similar manner to 
TetB, TetK-mediated tetracycline efflux was demonstrated to be dependent on 
the presence of divalent cations, such as Co2+, which are co-transported with 
tetracycline - transport of such a metal ion/tetracycline complex is coupled with 
proton transport.66 
TRIMETHOPRIM AND SULFONAMIDES 
Trimethoprim and the sulfonamides are synthetic agents that affect the 
biosynthesis of hydrofolic acid, an essential derivative used in amino acid and 
nucleotide synthesis. Sulfonamides are analogues of p-aminobenzoic acid that 
competitively inhibit the enzyme dihydropteroate synthase (DHPS), which 
catalyzes the condensation of dihydropteridine with p-aminobenzoic acid, an 
early step in tetrahydrofolic acid synthesis. Trimethoprim is an analogue of 
dihydrofolic acid that competitively inhibits the enzyme dihydrofolate reductase 
(DHFR). DHFR catalyzes the reduction of dihydrofolic acid to tetrahydrofolic 
acid, the final step of tetrahydrofolic acid synthesis. Cotrimoxazole, a 
combination of trimethoprim with a sulfonamide, has been used extensively to 
combat staphylococcal infections.67 
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Both high- (MIC greater than 1,000 j.tg/ml) and low- (MIC less than 100 
j.tg/ml) level trimethoprim resistance has been reported in both S. aureus and 
CoNS. I n some cases, chromosomally encoded low-level trimethoprim 
resistance may be due to overproduction of host DHFR. More commonly, 
however, resistance is encoded by the dfrA gene carried on the transposon-like 
element Tn4003. dfrA codes for a trimethoprim-resistant type S 1 dihydrofolate 
reductase that has been both biochemically purified and characterized. Tn4003 
has also been sequenced and it or similar dtiA encoding elements have been 
found on pSK1 family plasmids, large conjunctive plasmids, and on various other 
plasmids in both S. aureus and CoNS. Transposition of Tn4003 has not been 
experimentally demonstrated; rather, its apparent motility may be due to IS257-
mediated recombination events. The dtiA gene appears to be responsible for 
both high- and low-level resistance to trimethoprim in both S. aureus and CoNS. 
The differences in resistance correlate with differences in transcription caused by 
deletions adjacent to a copy of IS257 in Tn4003 affecting the promoter used by 
dtiA.68 
The chromosomal trimethoprim-sensitive DHFR gene from S. aureus has 
been cloned and sequenced and found to be distinct from dtiA (80 percent 
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identical at the amino acid level) and not located within an operon, suggesting 
that drfA did not originate from the S. aureus chromosomal DHFR gene. In 
contrast, the S. epidermidis trimethoprim-sensitive chromosomal DHFR gene 
differs from drfA by only 4 bp and is found in an operon-like structure, strongly 
suggesting that drfA originate from the S. epidermidis chromosomal gene. Site-
directed mutagenesis of drfA and kinetic analyses of purified DHFR's has 
indicated that a single alteration is largely responsible for the trimethoprim 
resistance. 69 
FLUOROQUINOLONES 
Fluoroquniolones such as norfloxacin, ciprofloxacin, and pefloxacin are 
synthetic broad-spectrum antimicrobial agents that interfere with the function of 
DNA gyrase, an essential enzyme involved in DNA replication and repair. 
Fluoroquinolone resistance has arisen rapidly in the staphylococci following the 
use of these agents in recent years to treat both gram-positive and gram-
negative bacterial infections. Three distinct loci have been identified in S. aureus 
that are involved in conferring resistance to fluoroquinolones. 7o 
First, target alterations in DNA gyrase can decrease the fluoroquinolone 
sensitivity of this enzyme. DNA gyrase is a tetrameric enzyme with two subunits 
(A and B) encoded by the gyrA and gyrB genes, which are homologous to their 
counterparts from other bacteria such as E. coli and B. subtilis. Sequencing of 
rnutant alleles of gyrA from a very large number of independent fluoroquinolone-
resistant isolates has indicated that mutations conferring fluoroquinolone 
resistance are located within a single region near codon 84. Additionally, gyrB 
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mutants have been identified that confer lower levels of resistance than gyrA 
mutants. These mutants were found to have substitutions at codon Asp-437 or 
Asp-458. Transformation of these gyrA or gyrB fluoroquinolone-resistant 
mutants with wild type gyrA or gyrB plasmids reconferred fluoroquinolone 
susceptibility in these strains, confirming that mutations in gyrA and gyrB are in 
fact responsible for the fluoroquinolone resistance. In addition, purified DNA 
gyrase from fluoroquinolone-resistant gyrA mutants has been shown in vitro to be 
resistant to approximately 20-fold higher concentrations of the agent than purified 
wild-type enzyme from fluoroquinolone-sensitive strains. 71 
Secondly, low-level fluoroquinolone resistance appears to be associated 
with mutations in the chromosomal grlA gene of S. aureus. The S. aureus grlA 
and grlB genes encode for homologues of GyrA and GyrB, which have been 
demonstrated to catalyze ATP-dependent DNA relaxation. Analysis of 
fluoroquinolone-resistant S. aureus mutants has indicated that mutants resistant 
to low levels of fluoroquinolone contained substitutions at Ser-80 of GrIA. Work 
with stepwise-selected mutants has indicated that mutations in grlA are required 
for expression of resistance due to gyrA mutations. Thus, low-level resistance is 
conferred by grlA mutations, but high-level resistance is a result of mutations in 
both grlA and gyrA. Thirdly, a chromosomally encoded active fluoroquinolone 
efflux system encoded by the norA gene has been described in S. aureus. The 
norA gene has been cloned and sequenced and found to encode a membrane 
protein. Sequence analyses have indicated that NorA is a member of the major 
facilitator superfamily of transporter proteins and is closely related to other drug 
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efflux proteins, some of which were mentioned earlier. Drug transport studies in 
whole cells and everted nlembrane vesicles have indicated that NorA mediates 
the active efflux of fluoroquinolone driven by the pmf. norA has also been shown 
to confer resistance to a range of compounds structurally unrelated to the 
fluoroquinolones and the norA gene has also been found in fluoroquinolone-
sensitive staphylococcal strains. An initial report suggested that fluoroquinolone 
resistance was due to a single base pair change in norA, resulting in a single 
amino acid change in its product. However, sequencing of the complete norA 
gene from both sensitive and resistant S. aureus strains failed to detect any 
differences within the gene?2 
MUPIROCIN 
The antibiotic mupirocin (pseudomonic acid A) is an isoleucine analogue 
that competitively inhibits isoleucyl-tRNA synthetase (IRS), preventing protein 
synthesis. Mupirocin has been used as a topical agent in the treatment of gram-
positive bacterial infections since its introduction in 1985. Interestingly, mupA 
has been detected in staphylococcal strains dating from 1965, well before the 
introduction of mupirocin as a topical agent. High- (MIC greater than 1,000 
J.lg/ml) and low- (MIC 8 to 256 J.lg/ml) resistance to mupirocin has been detected 
in both S. aureus and CoNS. Low-level resistance is probably due, in most 
cases, to mutation in the host IRS.73 Strains resistant to high levels of mupirocin 
have been shown to contain two biochemically distinct IRS enzymes: the na'lve 
mupirocin-sensitive IRS enzyme and an additional IRS enzyme that is less 
sensitive to inhibition by mupirocin. The mupA gene that codes for a mupirocin-
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resistant shares significant sequence similarity with a number of different 
bacterial IRS enzymes and contains characteristic IRS-specific motifs involved in 
ATP hydrolysis and amino acid activation. The mupA gene is, however, distinct 
from the chromosomal I RS gene, as they share only 30 percent similarity at the 
amino acid level. Thus, high-level mupirocin resistance in S. aureus appears to 
be due to the acquisition of an IRS gene from another organism, possibly in an 
analogous manner to the acquisition of trimethoprim resistance, as discussed 
previously. The mupA gene has demonstrated to be plasmid encoded in a rage 
of epidemiologically independent S. aureus and CoNS strains. Analysis of the 
mupA plasmids of pG0400 and pl3358 has indicated that the gene is flanked by 
directly repeated copies of the insertion sequence IS257. Analysis of other 
staphylococcal plasmids has suggested that IS257 has played a role in horizontal 
transmission of the resistance gene, as was suggested for previous examples.74 
VANCOMYCIN AND TEICOPLANIN 
Glycopeptide antibiotics, such as vancomycin and teicoplanin, form 
complexes with the peptidyl-o-Ala-o-Ala terminus of the peptidoglycan precursors 
at the outer surface of the cytoplasmic membrane, leading to the inhibition of 
transglycosylation and transpeptidation steps of cell wall synthesis. Since the 
development of multiresistance staphylococcal strains, vancomycin has 
frequently been the only drug available to the clinician for the treatment of 
serious infections caused by MRSA. Staphylococcal strains with reduced 
susceptibility to both vancomycin and teicoplanin have been isolated. In clinical 
strains of CoNS, resistance to both has also been noted, although more 
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commonly, strains are resistant to teicoplanin (MIC less than 128 }lg/ml) but 
sensitive to vancomycin (MIC less than 4 }lg/ml). In particular, S. haemo/yticus 
displays a propensity for developing resistance to glycopeptides in a single step 
upon exposure. Clinical isolates of S. aureus have been detected which have 
low-level resistance to both vancomycin and teicoplanin, while mutants of 
S.aureus have been selected in vitro with decreased susceptibility to both as 
well?5 A number of studies of glycopeptide-resistant staphylococcal strains 
have indicated that resistance is typically constitutively expressed, 
chromosomally encoded, and is stable in the absence of selective pressure. 
Clinical isolates of teicoplanin resistant staphylococci have been found to 
express a 39-kDa protein associated with the membrane to cell wall of the 
organisms. Kaatz et al detected a teicoplanin-resistant isolate from a single 
patient following unsuccessful therapy. Tn551 insertion mutants obtained of this 
strain regained teicoplanin susceptibility. These insertions were mapped to a 
single Sma1 chromosomal fragment. Analysis of the resistant strain indicated 
that expressed a 35-kDa membrane protein and had increased expression of 
both PBP2 peptides relative to the Tn551 insertion mutants. Moreover, its cell 
wall physiology was altered in some aspects.?6 In a similar study, analysis of 
clinical S. aureus isolates with decreased susceptibility to vancomycin from 12 
patients indicated that the majority expressed a 35-kDa membrane protein with 
increased expression of both PBP2 peptides as well.?? 
Vancomycin- and teicoplanin-resistant S. aureus mutants have been 
obtained in vitro by serial incubation in the presence of a low concentration of 
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either compound. Daum et al isolated mutants exhibiting low-level vancomycin 
resistance that showed alterations in cell wall organization and constitutively 
produced a 35-kDa protein. The ddh gene encoding this protein has been cloned 
and sequenced and codes for a cytoplasmic protein with sequence similarity to 0-
lactate dehydrogenase (o-LDH) and to the enterococcal VanH protein (discussed 
later). ddh was shown to be expressed in wild-type staphylococci, and 
expression was found to be increased in a glycopeptide-resistant mutant, which 
was associated with increased o-LDH activity. This possibly suggests that 
overexpression of o-LDH in S. aureus may contribute to low-level glycopeptide 
resistance. As mentioned earlier, decreased susceptibility to glycopeptides in 
the staphylococci also appears to be associated with expression of a 35- or 39-
kDa membrane protein, often accompanied by increased expression of PBP2 
peptides and apparent alterations in the cell wall physiology of the organism. 
Despite the similarity in size, these 35- or 39-kDa proteins probably do not 
correspond to Ddh, as Ddh is a cytoplasmic protein. Therefore, the 
mechanism(s) of glycopeptide resistance in these strain(s) still remain to be 
clarified.78 
In the better-studied enterococci, transferable high-level resistance to 
vancomycin (MIC greater than 512 J.lg/ml) with concomitant resistance is 
commonly seen and is referred to as VanA type resistance. This phenotype has 
been shown to be encoded by the vanA gene cluster on the 10.8 kb transposon 
Tn 1546, which is often carried by conjunctive plasrnids with a broad host range in 
gram-positive bacteria. Tn 1546 includes three genes essential for glycopeptide 
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resistance: vanA, which encodes an alternative o-Ala-o-Ala ligase that produces 
altered peptidoglycan side chains, containing an terminal dipeptide (e.g. o-Ala-o-
lactate) with greatly reduced affinity for glycopeptide antibiotics; vanH, which 
encoded a dehydrogenase that reduces pyruvate to o-Iactate, a substrate for the 
vanA product; and vanX, which encodes a 0, o-dipeptidase that hydrolyzes o-Ala-
o-Ala produced by the host ligase. Tn 1546 also includes two accessory 
glycopeptide-resistance genes: van Y, encoding a 0, o-carboxypeptidase that 
cleaves the C-terminal o-Ala of peptidoglycan precursors, and vanZ, which 
encodes a teicoplanin-resistance determinant; two genes, vanR and vanS, 
encoding a two-component system that regulates expression of glycopeptide 
resistance; and two transposition genes. Two other types of glycopeptide 
resistance, VanS and VanC, have also been identified in the enterococci. Like 
VanA resistance, these rely on the production of o-Ala-o-Ala ligases. The vanB 
gene cluster, which encodes a vancomycin-resistant, teicoplanin-sensitive 
phenotype, is encoded on the 64-kb composite transposon Tn 1547. 
Significantly, Tn 1547 is bounded on one side by the staphylococcal insertion 
sequence IS256 and on the other by IS 16, which is highly similar to IS256?9 
Unlike the enterococci, reduced susceptibility to vancomycin and 
teicoplanin in the staphylococcal appears not to be due to ligases with altered 
substrate specificity, since resistant staphylococci produce peptidoglycan 
precursors terminating in o-Ala-o-Ala. High-level vancomycin resistance as seen 
in the enterococci has not been observed in clinical staphylococcal strains. 
However, the conjunctive co-transfer both in vitro and in vivo of vancomycin 
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resistance, along with other resistances, from E. faecalis to S. aureus has been 
demonstrated. The S. aureus transconjugants were subsequently resistant to 
high levels of vancomycin, although they were unable to transfer resistance to 
other S. aureus strains and resistance was lost in the absence of selective 
pressure.80 Thus, it seems likely that the emergence of staphylococcal strains 
resistant to high levels of vancomycin is only a matter of time. This scenario 
would have great ramifications for the treatment of serious S. aureus infections. 
However, it is hoped that with the growing knowledge of the mechanistic basis of 
resistance and its evolution at the molecular and genetic level, new strategies 
can be devised to reduce the impact of this devastating public health problem. 
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Figure 1: Kinetic parameters of the four variants of ~-Iactamase of Staphylococcus aureus 
Type A Type B TypeC Type D 
~-Iactam Kcat Km REH Kcat Km REH Kcat Km REH Kcat Km REH 
Cephaloridine 1.95 10.9 100 6.65 19.4 191 5.61 11.5 273 1.25 7.9 88 
Cefazolin 1.01 18.4 31 4.68 254 10 3.94 267 9 1.91 49.9 21 
Nitrocefin 23.2 6.4 2,034 16.5 15.7 587 13.7 20.4 293 25.6 5.9 2,424 
Benzylpenicillin 171 51.1 1,869 156 38.6 2,258 210 55.9 2,098 46 112.6 228 
Ampicillin 308 255 675 412 160 1,438 355 122 1,685 133 129 571 
Abbreviations: Kcat molecules of substrate hydrolyzed per second; Km, in Jlm; REH, relative efficiency of hydrolysis (Kcat/Km) relative to cephaloridine set at 100 
(Data from Rowland et al) 
